




Oncidium
foundation

2025 Impact Report



Striving for **Equal Access** to Radioligand Therapy
for Cancer Care for **Everyone, Everywhere.**

Table of Contents

Presenting the foundation	5
Hope	9
Access	15
Education	21
Finance & Governance	29

 Malena was a teenager when cancer entered her life, and she met it with strength, going through multiple intensive treatments, and then came another battle, a legal fight against medical coverage that repeatedly refused to fund the care her doctor recommended.

When standard options were no longer enough, a nuclear medicine treatment became a new possibility and the Oncidium foundation enabled her treatment in Argentina, giving Malena more time and more quality of life. 

Deborah and Adrián, Malena's parents

Malena has since passed away, but her journey remains a message of resilience and purpose. We carry her in our hearts, and we continue this work so that others do not have to fight twice, once against cancer, and once against access.



Find the entire story of Malena here

Oncidium foundation in figures

Hope



Access



Education



Presenting the foundation

Advancing equal access to radioligand therapy for cancer care, for everyone, everywhere.



The Oncidium foundation is an independent non-profit & public-benefit organization striving toward equal access to radioligand therapy for cancer care for everyone, everywhere.

Three pillars to change lives



Hope

- Supporting patients in need through treatment funding and access initiatives.
- Advancing research and development in radioligand therapy.



Access

- Building a global community to improve access to radioligand therapy.
- Helping patients find treatment.



Education

- Providing patients and healthcare practitioners with essential, practical knowledge.
- Expanding awareness to support informed decision-making

From an idea to a lasting mission

Foundation Established

Creation of the foundation by Dr. Richard Zimmerman and co-founders.



First Major Donation

The first donations from Dr. Christian Behrenbruch and Dr. Andreas Kluge marked a defining moment, transforming the foundation from a promising idea into a concrete, operational organization.

Operational Team Formed

Rebecca Lo Bue was appointed CEO, marking the start of building the foundation's operational team.



First Patient Treated

Dr. Fernando Acosta became the first patient treated with donated doses of Lutetium-177 PSMA, facilitated by the Oncidium foundation.



First Research Project Supported

Launch of our first supported research project: the NOBLE Registry.

RLT-Connect Launched

RLT-Connect, a treatment donation platform was launched to make radioligand therapy accessible to patients in financial need.



Partnership with the IAEA

A practical arrangement (PA) was signed, marking the start of a strategic collaboration to work on multiple projects together and increase impact.



Four values to guide us



Care
working to ensure equitable cancer care for everyone.



Collaboration
uniting across continents and disciplines to tackle challenges together.



Trust
acting with transparency and integrity in all that we do.



Engagement
enhancing with intention and responsibility, honoring commitments to advance our mission.



As the field of nuclear medicine grows in importance, there is a need for patient advocacy groups that are able to build awareness and connect patients to treatment options. This visionary idea motivated me to become an early participant in the creation of the foundation.



Dr. Christian Behrenbruch
Co-founder, MD and CEO at Telix Pharmaceuticals




Observing the global momentum of radionuclide therapy, I felt the need to support the Oncidium foundation, as it strives to bridge gaps for a broader understanding of the existence and benefits of such options and brings us closer to our shared goal.



Dr. Andreas Kluge
Owner, ABX-CRO and Pharmaceuticals Consultant

What is radioligand therapy?

Radioligand therapy is a form of targeted treatment available in cancer care that uses radioactive molecules designed to bind to specific receptors on cancer cells. Once attached, the radioactive component delivers localized radiation to eliminate the target cells while sparing much of the surrounding healthy tissue. It offers people living with cancer targeted and personalized care.




Radioligand therapy in the world

Radioligand therapy is known with different names worldwide: Radiotheranostics, Targeted Radionuclide Therapy, Radiopharmaceutical Therapy, Molecular Radiotherapy, Radioisotope Therapy, Nuclear Medicine Therapy, or Peptide Receptor Radionuclide Therapy (PRRT)

Radioligand therapy (RLT) remains inaccessible in most countries worldwide, mainly due to limited nuclear medicine infrastructure and uneven reimbursement; even where therapies are approved by the health regulatory authority, funding is often incomplete and comes late in the treatment.

RLT status in number of countries²



Today, RLT is formally approved for prostate cancer (PSMA-targeted) and GEP-NETs (SSTR-targeted), with thyroid cancer covered by long established radioiodine therapy. The field is rapidly expanding, with over 400 ongoing clinical trials investigating new targets and cancer types¹, including pancreatic, breast, kidney, hepatocellular carcinoma, and brain tumors, highlighting the strong global momentum despite persistent access and affordability barriers.

1. Ninatti G, Lee ST, Scott AM. Radioligand Therapy in Cancer Management: A Global Perspective. Cancers (Basel). 2025 Oct 23;17(21):3412. doi: 10.3390/cancers17213412. PMID: 41228206; PMCID: PMC12607575.


2. Global Maturity Level Analysis. (2025) Oncidium Foundation

Hope

Mobilising donated doses and expertise, RLT-Connect expands access to radioligand therapy for patients in need.



RLT-Connect: Changing lives, one patient at time



22 patients treated
86 doses donated

2024

52 patients treated
150 doses donated

2025

74
Patients treated through
RLT-Connect since creation

236+
doses donated
to patients in need

3.5M€
Treatment donation value



A global treatment donation program for patients in financial need.

RLT-Connect is a collaborative platform established by the Oncidium foundation to facilitate access to radioligand therapies for cancer patients who cannot afford them. The platform connects healthcare practitioners and radioisotope companies that donate radioisotope doses, enabling treatment for patients in financial need. Since the beginning, RLT-Connect has successfully facilitated the treatment of 74 patients across 15 countries. We are now working to expand the program to as many countries as possible.

Our Goal? With an ambitious objective to rally stakeholders, we are committed to help 365 patients get access to their RLT treatment within five years, advancing access to cancer care.



Discover
RLT-Connect

Stories of Hope

Behind every number is a patient and a story of resilience. Some accessed radioligand therapy with support made possible through our network. Others did not benefit from RLT-Connect, yet still shared their journey to inform and support others. These voices are why RLT-Connect exists: to turn compassion into action when access becomes a barrier.



Fernando, AG



Sanctus, TZ



Luciano, AG



Steve, US



Aparecido, BR



Hugo, BE



Stanton, ZA



Tom, US



Luis, AG



Mr. Roger, CA



Kehari, IN



Bharatlal, IN



Mr. Abel, EG



Mr. Mochato, ZA



John-Antoine, EG



Malena, AG



Thanks to the doses facilitated by the foundation, I was able to start and complete the treatment successfully, on time and in full. It was truly a success. Today I can enjoy a normal quality of life, and I feel very well. I am deeply grateful to the foundation, to the doctors who cared for me, and to my family and friends. Thanks to all of them, I can walk through life with faith and great hope. ■■■


Jorge Raul Leiva
Prostate Cancer - Argentina


I travelled to India for treatment, but the therapy recommended for me was extremely expensive and difficult to access. It felt impossible for someone like me to afford it. Without the support of the Oncidium foundation, I could not have received the treatment that I urgently needed. ■■■


Mohammad No Haq
NET - Bangladesh

IAEA Partnership

In September 2025, the Oncidium foundation signed a collaboration agreement with the International Atomic Energy Agency (IAEA) under its Rays of Hope initiative. The partnership aims to expand access to radioligand therapy (or Targeted Radionuclide Therapy) in low- and middle-income countries by addressing regulatory, technical, and production challenges. Together, the IAEA and Oncidium will raise awareness, build capacity, and foster partnerships to accelerate the adoption of innovative radioligand therapies, bringing precision cancer treatment to patients.

We express our sincere appreciation to the Permanent Mission of Belgium to the IAEA for its continued support in advancing the Oncidium foundation's mission.



Atoms for Peace and Development

■■■ By working with the Oncidium foundation under the Rays of Hope initiative, we are strengthening global efforts to ensure that advanced cancer care, including nuclear medicine, is not limited to a few but made available to all who need it. ■■■

Rafael Mariano Grossi,
Director General of the IAEA.



From left to right: Dr. Eric Van Walle, Oncidium Board Member; Bernard Quintin, Belgian Minister of the Interior, Institutional Reform and Democratic Renewal; Rebecca Lo bue, CEO of the Oncidium foundation; Rafael Mariano Grossi, Director General of the IAEA.; Mr. Mathieu Bihet, Belgian Minister of Energy

Supporting programs to expand RLT

The Oncidium foundation also supports projects in the field of nuclear medicine, with a focus on improving access to radioligand therapy for patients. We help communicate the results of these projects and clinical trials to people living with cancer, healthcare professionals, and nuclear medicine practitioners, ensuring that patient needs and perspectives remain at the center of our work.



Co-funded by the European Union

Accelerate.eu

Accelerate.EU is a project pioneering the development of novel radiotheranostic pairs featuring the alpha-emitting isotope astatine-211 (^{211}At) to target aggressive cancers like pancreatic, breast, and brain cancer.

Occelerate.EU
ihi-accelerate.eu

Thera4Care

Thera4Care specializes in advanced theranostic solutions, combining expert research with novel technologies to revolutionise healthcare. Our approach enhances precision in both diagnostics and treatments for complex diseases like cancer, utilizing innovative isotopes and imaging techniques to improve patient outcomes.

THERA4CARE
thera4care.eu

RLT4BE

RLT4BE is a government-supported initiative bringing together key stakeholders to develop an integrated solution framework and actionable plan to ensure Belgium is future ready for the implementation and expansion of radioligand therapy in cancer treatment.

RLT4BE
RADIOLIGAND THERAPY ACTION PLAN


Access

Facilitating access to RLT and developing an international network of solidarity



Building a global community to improve access to radioligand therapy.

Less than,
5%
of eligible patients
get RLT*



Today, less than 5% of eligible patients get access to radioligand therapy. To bridge this gap, the Oncidium foundation collaborates with experts worldwide, including our Ambassadors, who actively participate in our projects. Their insights and engagement help us deliver impactful, sustainable solutions for patients everywhere.

Global perspective, local actions

While people living with cancer are at the heart of the Oncidium foundation, our ambassadors are the driving force behind our global outreach.

Ambassadors help spread awareness, share knowledge, and open doors to radioligand therapy in their countries and beyond. By volunteering as an Ambassador, individuals become vital voices in the movement to improve access, advance education, and build hope for people living with cancer around the world.

We are supported by 165 dedicated ambassadors representing 65 countries across five continents. Our long-term goal is to have

at least one ambassador in every country. Achieving this will require continued investment in research, development, and access initiatives.

Ambassadors play a crucial role in suggesting and identifying key projects focused on improving patient access, advancing education, and supporting the development of radiotheranostics.

*Source: Radiotherapy and theranostics: a Lancet Oncology Commission, published online September 30, 2024. Estimation based on Pluvicto revenue, expanded access programs, and clinical trials for compassionate use. Methodology adapted from The Lancet Oncology.



As ambassadors of Oncidium, we transform collaboration into meaningful impact for people living with cancer. In Argentina, we focused on improving access through education, awareness and partnerships with hospitals and industry, ultimately opening doors for patients who previously could not access it, and laying the groundwork to reach many more. ■

Dr. María Bastianello
Oncidium Ambassador in Argentina




Supporting patients in finding treatment

A treatment center finder to help patients find where to get treated.

In the foundation's early days, we recognized that an essential tool for improving patient access to radioligand therapies was missing: a global map showing centers already delivering these therapies.

This tool provides the location and contact details of the nearest hospital that can determine whether an individual is eligible for radioligand therapy. Currently, over 1000 centers are registered on our website. We update this list regularly to support patients in finding the nearest center providing radioligand therapy. All centers that wish to register can do so directly on the website.

1000+
Therapy centers references in our map

Explore the map and
Register your therapy center

USA subsidiary: Oncidium foundation USA recognized as a 501(c)3 organization

Established in 2024, **Oncidium foundation USA** represents a major step in extending the global mission of the Oncidium foundation into the U.S. healthcare landscape. In 2025, The U.S. Internal Revenue Service has officially recognized Oncidium foundation USA as a 501(c)(3) tax-exempt public charity, marking the key milestone that officially enables the subsidiary to become fully operational. With this certification, the foundation is now positioned to advance its core goals in the U.S.: educating patients and health care providers, strengthening equitable access to radioligand therapy and molecular imaging, and connecting American innovation with global clinical adoption.

As the subsidiary enters its first operational year, Oncidium foundation USA is preparing a robust national awareness and education campaign in partnership with clinicians, researchers, and advocacy organizations. Planned activities include participation in major scientific and medical conferences such as SNMMI, ASCO, AUA, and ASTRO. This strengthened U.S. presence enhances our ability to drive collaboration, empower patients, and advance the integration of advanced molecular medicine across health systems.



New discoveries are being made every day on potential new treatments for patients with radiotheranostics. We are focusing with the Oncidium foundation on finding hope for people living with cancer. Many patients don't know about radiotheranostics, and I've dedicated my career as a pharmacist and radiochemist to clinical trials and ensuring patients can receive new treatment options. I am really happy to support these patients as fully as possible, not only in the United States but all over the world, alongside all the Ambassadors of the Oncidium foundation.

Dr. Jean-Luc Vanderheyden
Head of The Oncidium foundation USA

”

Shaping change in cancer care through patient engagement



In 2025, the Oncidium foundation is preparing to launch its Patient Engagement Program to strengthen collaboration with the communities we serve and ensure that patient experience meaningfully shapes our work. Through this program, we aim to partner with people living with cancer and organizations worldwide to

improve access to radioligand therapy, provide clear and accessible educational resources, and support advocacy efforts at local, national and global levels. We will also invest in research tools to collect real-world patient insights, reinforcing our commitment to evidence-based practice and enabling progress across all program priorities.

Collaborations with institutions

In 2025, the Oncidium foundation strengthened its collaborative network through strategic partnerships with leading institutions such as the International Atomic Energy Agency (IAEA), the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), ALASBIMN, BioWin, IPEN, INCA and Hospital de Amor. These collaborations foster scientific exchange and education in theranostics and molecular radiotherapy, enhancing global access to radioligand therapies.




Education

Empowering people living with cancer, caregivers, and healthcare professionals with clear, reliable information to support better decisions.



Guiding understanding in cancer care

Radioligand therapy offers hope to many people living with cancer, but it can also feel complex and difficult to understand. At the Oncidium foundation, we believe that access to care starts with awareness and education.




Our initiatives are designed for three key audiences. For people living with cancer, we provide clear, patient-friendly resources to help them understand their options and feel more confident throughout their care journey. For healthcare professionals, we share expert led content and practical tools that support referrals and multidisciplinary collaboration. For the nuclear medicine community, we encourage training, knowledge exchange, and collaboration to help integrate radioligand therapy into everyday clinical practice worldwide.

Through education and awareness, we work to make innovative cancer care more visible, better understood, and more accessible to those who need it most.

65k+

Views on
educational content



Throughout my care journey, what helped me most was being proactive in doing research, asking questions, not hesitating, and daring to ask my doctors for what I needed, as well as seeking support from patient associations or foundations like Oncidium.

Discover
Tiphaine's Story



People living with cancer

Providing accessible resources to support informed, confident decisions.

Our initiatives empower patients to understand their treatment options, make informed decisions, and feel confident throughout their care journey. These include a variety of formats, such as podcasts, national TV programs, webcasts, as well as our Mr. Bind comic book and RLT channel.

Our ambassadors, Dr. María Bastianello and Dr. Fernando Acosta, appeared on a national TV channel in Argentina to share their experience with radioligand therapy. Fernando was the first patient the foundation helped receive radioligand therapy, and his journey inspired the RLT-Connect initiative.

During the show, Maria explained how this approach can change patient care, while Fernando spoke about his personal journey and the impact radioligand therapy had on his life. Their intervention helped raise public awareness about access to radioligand therapy.



Mr. Bind: demystifying RLT with comics



Conversations with nuclear medicine practitioners highlighted a clear need for tools to explain radiotheranostics to newly diagnosed cancer patients. In response, we collaborated with Dr. Jérémie Calais and other experts to create educational videos and a comic book featuring Mr. Bind and his companions, engaging characters who simplify complex concepts.

Today, the Mr. Bind videos and comic are used worldwide, reaching patients, healthcare professionals, and the wider public with thousands of copies distributed worldwide.



RLT Channel: radioligand therapy explained for everyone

Bringing radiotheranostics to the forefront of cancer care

The RLT Channel is evolving into one of our key initiatives, offering a recurring platform to spotlight various cancers and explore their treatment possibilities through radiotheranostics. Each program is designed to provide comprehensive insights on a specific cancer type, from addressing global challenges to highlighting local perspectives and advancements.



Episode 1: Prostate Cancer's New Hope: RLT in Action - Global and Belgium Focus

This episode is designed for individuals living with prostate cancer and their loved ones. Its goal is to demystify radioligand therapy (RLT) by offering clear and practical information, helping you understand how the therapy works, its potential benefits, and how it can be integrated into the care pathway.

Episode 2: Understanding Neuroendocrine Cancers & How RLT can Help Improve Quality of Life

This episode focuses on neuroendocrine tumors (NETs), exploring the latest developments and remaining challenges worldwide, and providing a clear overview of current NET care pathways.

Through expert insights and accessible explanations, it highlights the role of radioligand therapy in today's treatment pathways and helps patients and families better understand available care options, eligibility pathways and referral processes.

Release in February 2026



Watch episodes
on YouTube



Healthcare professionals

Collaborating with healthcare professionals to enhance patient referrals

Reaching oncologists, urologists and other healthcare practitioners is essential to expanding access to radiotheranostics, as they guide most treatment decisions for metastatic cancer patients. In 2025, we focused on strengthening our presence within these communities to ensure radioligand therapy is recognized, considered earlier, and more routinely integrated into cancer care.

Throughout the year, we engaged healthcare professionals at key international events, including ASCO, ESMO, the European Cancer Summit, EAU, AORTIC, UroteragLatam and the World Cancer Series, opening conversations on referral pathways, multidisciplinary collaboration, and the potential of combined therapies. These exchanges helped us identify opportunities to bring patients closer to radiopharmaceutical options.

We also launched a Blue November campaign, *#BlueNovemberWithRadiotheranostics*, developed in collaboration with PRAISE-U, the Ontario Institute for Cancer Research, and XCancer. The campaign united experts from urology, oncology, and nuclear medicine to promote practical ways to integrate radiotheranostics into prostate cancer care.



Nuclear medicine community

First patients treated following two on-site trainings

In 2025, the foundation supported two on-site trainings to prepare local staff for the safe preparation and delivery of radioligand therapy. In both cases, two patients could be treated with ¹⁷⁷Lu-PSMA by the newly trained staff.

IAEA's national theranostics course in Kenya

The foundation proudly supported an IAEA-led training at KUTRRH in Kenya, marking our first official collaboration with the agency. This training enabled the country's first-ever public-sector administration of ¹⁷⁷Lu-PSMA therapy.

By donating the Lutetium doses and working alongside local and international experts, we helped ensure that the medical team could confidently deliver this advanced theranostic treatment. This achievement marks the beginning of a new chapter for equitable access to advanced cancer treatment in Kenya's public sector. November 2025.



University Hospital of Ibadan in Nigeria

Our Ambassador Dr. Janke Kleynhans conducted a training session at the University Hospital of Ibadan in Nigeria to both train local staff on labelling and quality control with ¹⁷⁷Lu-PSMA radiopharmaceuticals and treat a patient with ¹⁷⁷Lu-PSMA. July, 2025



I believe deeply in Oncidium's mission to expand access to radiopharmaceutical therapy for patients who would otherwise never have the chance to receive it. What matters most to me is hands-on impact, from supporting training on the ground to helping build sustainable capacity in underserved regions.

Dr. Janke Kleynhans

Oncidium Ambassador in Belgium



Fostering collaboration and innovation to improve the integration of RLT in cancer care worldwide

In 2025, we focused on creating spaces, both online and at international events, where professionals could exchange insights, learn from patient experiences, and stay informed about the evolving RLT landscape. We had a strong presence worldwide, participating in several events across all regions.

Patient sessions

We created or supported dedicated patient sessions, ensuring that patient voices were at the heart of scientific discussions and reinforcing the importance of patient-centred communication in radiotheranostics.



- ICPO forum, Germany
- Dubai Radiotheranostics Summit
- Journée RIV, France
- UroTerag, Mexico
- Radiotheranostics Conference, Egypt

A complete state of the current radiotherapeutics

We offer educational resources designed to support the healthcare professionals community and share updates on the field's latest developments.

- Theranostics Insights: a monthly scientific content series featuring a deep dive into the mechanisms and wide-ranging medical applications of a specific radiopharmaceutical.
- Radiotheranostics Today: a comprehensive look into the rapidly advancing field of radiotheranostics, including exclusive interviews and detailed articles from leading experts worldwide.
- Radiotherapeutics library on our website: overview of radiotherapeutic treatments in cancer care. This resource details approved therapies, those that have been discontinued, and those still in development.



Read our newsletter here

4th Edition of the Tackle Cancer Challenge

The Tackle Cancer Challenge is a virtual sports event where participants can interact globally by practicing different types of sports and raise awareness about radiotheranostics. This year, we collectively achieved over 60,000 km thanks to more than 500 participants from 55 countries.



Through the challenge, the initiative encourages collective engagement and solidarity. All funds raised are reinvested into the RLT-Connect platform, our patient-centred initiative designed to help individuals access radioligand therapy. By combining physical challenge with purpose, the Tackle Cancer Challenge turns movement into action for better cancer care.



60 000
km covered


55
Countries


500
Participants


Finance & Governance



The team

Based in Belgium, the foundation is powered by a team of 17 staff members with diverse backgrounds, all united by a common mission: ensuring that everyone living with cancer can access accurate information and innovative treatment options, regardless of where they live or their financial situation.

To turn this mission into action, our work is organized into three dedicated departments: Access, Education, and Hope, each addressing a key dimension of patient support and cancer care development.

Guided by care, collaboration, trust, and engagement, our team works closely with healthcare professionals, institutions, and patient communities worldwide, building partnerships and initiatives that advance equitable cancer care and make a tangible difference in the lives of people living with cancer.



Board of Directors



Richard Zimmermann, PhD, President & Co-Founder

Independent consultant in the Radiopharmaceutical field (Chrysalium Consulting, Lalaye, France), co-founder of MEDraysintell, initiator of the Belgian rad4med.be network and co-founder of Global Morpho Pharma SARL (France).



Eric van Walle, PhD, Vice-President

Former General Manager, SCK•CEN (Studiecentrum voor Kernenergie – Centre d'Etude de l'Energie Nucléaire, www.sckcen.be), Mol and Brussels, Belgium.



Bruno Scutnaire, Board Member

Operations Director Industrial at IBA Industrial Solutions (Ion Beam Applications), Louvain-La-Neuve, Belgium.



Jérôme Majoie, Board Member

CEO of the Foundation Fournier Majoie, a Belgian entity committed to empowering entrepreneurial efforts in the battle against cancer.



Soumya Chandramouli

Chief Financial Officer at Novadip, a biotech company focused on bone and tissue regenerative medicine, Mont-Saint-Guibert, Belgium.

Scientific board

The Oncidium foundation is supported by a scientific board of international nuclear medicine experts who provide guidance on research and innovation. Their expertise ensures that our educational content, aimed at both patients and healthcare professionals, is scientifically accurate and clearly communicated.



Dr. Alice Viana, PhD, Advisory Board Chair, Belgium

Scientific Director at the Oncidium foundation. Alice leads all our scientific projects to ensure the accuracy of every piece of information we deliver.



Prof. Meera Venkatesh, PhD, Member, India

Nuclear Scientist with 40+ years work of experience in the various applications of nuclear technologies. Now retired, still devoting her time for humankind.



Dr. Omar Yehia Hussein, MD, Member, Egypt

Radiology and Nuclear medicine physician. Director of PET/CT units at Misr Radiology Center.



Dr. Jeremie Calais, MD, PhD, Member, USA

Associate Professor and Director of the Clinical Research Program of the UCLA Nuclear medicine and Ahmanson Translational Theranostics Division. He is a Certified Principal Investigator (CPI) by The Association of Clinical Research Professionals (ACRP).



Dr. Vasko Kramer, PhD, Member, Chile

As head of R&D, Vasko is continually working on several new radiopharmaceutical developments and collaborating with other sites to help them get access to radioligand therapy (RLT).

Finance


The foundation's funding currently comes from:

- **Donations from individuals, companies and non-profits** (both monetary and in-kind)
- **Grants from governmental authorities** (mostly European)
- **Partnerships with companies from the Nuclear Medicine field**

In 2025, thanks to the generosity of our contributors, the Oncidium foundation was able to support many projects around the world. On behalf of those we support, we would like to sincerely thank you for your contributions and commitment throughout the year.

The following pie chart shows how we allocated this year's contributions between our three pillars (Access, Education, Hope). 2025 has been marked by the growth of our activities across all fronts and the further professionalization of our operations.

The Oncidium foundation is audited annually by RSM Audit, an independent statutory auditor (réviseur d'entreprises). As a Belgian "fondation d'utilité publique" (public interest), the foundation fully complies with the legal and regulatory framework set out in the Belgian Code of Companies and Associations (CSA).



Governance

The Oncidium foundation's governance ensures transparency, accountability, and compliance with the Belgian Code of Companies and Associations (CSA), while enabling actions to expand global access to radioligand therapies.

Investment committee

The committee supports prudent and mission-aligned management of the Oncidium's assets.

- **Jerome Majoie** – Chair & Board Member Oncidium
- **Thomas Pevenage** – Director, Treasury & Financing at IBA
- **Rebecca Lo Bue** – CEO Oncidium
- **Gauthier Roelants** – CFO Oncidium
- **Lionel Doumont** – Permanent guest - CIO Oncidium / Founder Qiiwi

Conflict of interest

At the Oncidium foundation, integrity and transparency guide our governance. We follow strict procedures to identify and manage conflicts of interest, in full compliance with the Belgian Code of Companies and Associations. Board members must declare any potential conflict, withdraw from related decisions, and confirm annually that they uphold our ethical standards, ensuring independent and objective decision-making.

Our global ambassador network follows adapted guidelines to avoid any personal or institutional influence on their outreach activities. By encouraging early disclosure, providing clear guidance, and reviewing any potential issues, we maintain a culture of openness and accountability across all levels of the organization.

Take action now

Take action today to bring life-changing treatment to patients in need. Through a donation or collaboration with the Oncidium foundation, you can help expand access and give hope to those facing cancer worldwide.

Support our Mission



Make a donation or become a sponsor to help bring radioligand therapy to patients in need.

Improve Global Access



Register your hospital, join the RLT-Connect dose-donation program, or explore collaboration opportunities.

Volunteer with us



Contribute your time or skills — translation, awareness, outreach — or become an Ambassador in your region.

Contact: contact@oncidium-life.org

Raise Awareness



Share our mission on social media and help more patients learn about radiotheranostics.

Stay Connected



Subscribe to our updates to follow our projects, stories, and progress.



The conviction that every patient deserves equitable access to radioligand therapy, regardless of where they live, was the spark behind the creation of this foundation.

Our mission is built on that belief: **turning innovation into real, global access for patients who need it.**

Richard Zimmermann
Co-Founder & President Oncidium foundation



Thank you


Thank you to the patients and families who chose to share their journeys with us and trusted us with their stories. Your voices are at the heart of our work.

Thank you to Malena's family, Stanton and his mother, John Antoine and Mochato for their testimonies, and to all those who spoke up to help raise awareness, advance understanding, and support others along the way.

Thank you to those who support our mission worldwide: our ambassadors, healthcare professionals, partners, donors and supporters. Your commitment enables progress and helps turn our purpose into meaningful action.

Thank you to those who dedicate their time, expertise, and energy to advancing access, education, and hope for patients everywhere.

To those who are no longer with us, we extend our deepest gratitude for the time we shared. Your legacy lives on through the continued work of this organization.



**Oncidium
foundation**

Access • Education • Hope

Corporate Sponsors



Institutions and Programs Partners



RLT-Connect Sponsors



While all care has been taken to ensure that the information contained in this publication is correct, we accept no responsibility for any inaccuracy and reserve the right to modify this information.

The Report does not constitute legal, financial, medical, or investment advice. Nothing herein should be interpreted as a solicitation, recommendation, or endorsement of specific treatments, institutions, products, or services. Medical information reflects general knowledge at the time of publication and should not be used as a substitute for professional medical advice, diagnosis, or treatment.

All rights reserved.

The Oncidium Foundation is a Belgian *fondation d'utilité publique*, registered under number 0838.388.420 (RPM Brussels).